LSL Pharma Group Inc.
LSL.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 74.23% | 77.07% | 57.17% | 42.70% | 21.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 74.23% | 77.07% | 57.17% | 42.70% | 21.36% |
| Cost of Revenue | 45.69% | 37.56% | 19.43% | 0.23% | -19.28% |
| Gross Profit | 219.08% | 1,132.14% | 2,089.53% | 299.53% | 177.99% |
| SG&A Expenses | -12.31% | -10.89% | -23.77% | -31.20% | 37.91% |
| Depreciation & Amortization | 4.84% | -297.15% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.21% | 14.79% | -0.69% | -14.00% | -6.68% |
| Operating Income | 108.09% | 87.33% | 83.79% | 79.27% | 40.32% |
| Income Before Tax | 138.00% | 76.16% | 74.28% | 70.43% | -7.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 137.43% | 76.16% | 74.28% | 70.43% | -7.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 137.43% | 76.16% | 74.28% | 70.43% | -7.92% |
| EBIT | 108.09% | 87.33% | 83.79% | 79.27% | 40.32% |
| EBITDA | 150.40% | 108.02% | 100.36% | 91.77% | 47.14% |
| EPS Basic | 122.58% | 80.90% | 78.81% | 75.19% | 1.97% |
| Normalized Basic EPS | 81.11% | 71.18% | 70.88% | 69.44% | 38.67% |
| EPS Diluted | 119.37% | 77.58% | 75.15% | 71.72% | -2.90% |
| Normalized Diluted EPS | 81.11% | 71.18% | 70.88% | 69.44% | 38.67% |
| Average Basic Shares Outstanding | 32.79% | 26.40% | 22.89% | 21.97% | 19.20% |
| Average Diluted Shares Outstanding | 32.89% | 26.50% | 22.93% | 21.97% | 19.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |